The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease.

Patricia G. Synnott,R. Brett McQueen,Daniel A. Ollendorf,Jonathan D. Campbell,Steven D. Pearson

The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease.

2020

Patricia G. Synnott
R. Brett McQueen
Daniel A. Ollendorf
Jonathan D. Campbell
Steven D. Pearson

DISCLOSURES: Funding for this summary was contributed by Arnold Ventures, Commonwealth Fund, California Health Care Foundation, National Institute for Health Care Management (NIHCM), New England St...

Keywords:

Family medicine
Rivaroxaban
new england
Commonwealth
health care management
Health care
Disease
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations